8-K: MetaVia Inc. Announces Positive Phase 2a Topline Data for MASH Treatment and Provides Corporate Update

MetaVia Inc. released positive topline results from its Phase 2a trial of DA-1241 for MASH, showing significant improvements in liver health markers and plans to meet with the FDA in the first half of 2025.

Summary

• MetaVia Inc. has released an updated corporate presentation highlighting the positive topline results from its Phase 2a clinical trial of DA-1241, a GPR-119 agonist, for the treatment of MASH (Metabolic dysfunction-associated steatohepatitis).
• The trial met its primary endpoint, demonstrating a statistically significant reduction in ALT (alanine aminotransferase) levels, a key marker of liver damage, at the 100mg dose compared to placebo.
• The 100mg dose of DA-1241 also showed significant improvements in secondary endpoints, including a reduction in CAP (Controlled Attenuation Parameter) score, indicating reduced liver fat, and a reduction in FAST score, a measure of liver fibrosis.
• Additionally, the 100mg dose showed significant reductions in HbA1c levels from baseline compared to the placebo group.
• The company plans to meet with the FDA in the first half of 2025 to discuss the next steps for DA-1241.
• MetaVia also has an ongoing Phase 1 trial for DA-1726, a GLP1R/GCGR dual agonist for obesity, with interim data from the multiple ascending dose (MAD) part of the trial expected in Q1 2025.
• The company is well-capitalized with approximately $21.7 million in cash at the end of Q3 2024.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results and a clear path forward, suggesting a strong outlook for the company. The positive data and planned FDA meeting are encouraging.

Positives

• The Phase 2a trial of DA-1241 demonstrated statistically significant improvements in key liver health markers.
• The drug showed a strong safety and tolerability profile in the trial.
• The company has a strategic partnership with Dong-A ST, a major shareholder.
• MetaVia is well-capitalized with a substantial cash balance.
• The company has multiple near-term value-creating milestones.

Negatives

• The 50mg dose of DA-1241 did not show statistically significant results in the primary endpoint.
• The combination of DA-1241 with sitagliptin did not show a significant improvement over the 100mg dose alone.
• One subject experienced a treatment-related adverse event leading to study drug discontinuation.

Risks

• The company's future success depends on the ability to execute its commercial strategy.
• There are risks associated with regulatory submissions and obtaining regulatory approval for product candidates.
• The company's ability to realize the benefits of the license agreement with Dong-A ST is subject to risks.
• The company's clinical trials are subject to risks, including the ability to recruit subjects and achieve consistent results.
• Changes in applicable laws or regulations could impact the company's operations.
• The company's stock price could be affected by changes in market conditions and other factors.

Future Outlook

The company plans to meet with the FDA in the first half of 2025 to discuss the next steps for DA-1241 and expects interim data from the MAD part of the Phase 1 trial for DA-1726 in Q1 2025.

Management Comments

• The company is aiming to increase shareholder value through multiple, near-term, value-creating milestones.

Industry Context

The announcement is significant in the context of the growing need for effective treatments for MASH and obesity, and MetaVia's pipeline of next-generation therapeutics positions them well in this competitive landscape.

Comparison to Industry Standards

• The results of the DA-1241 Phase 2a trial are promising when compared to other MASH treatments in development, particularly in the reduction of ALT levels and improvements in CAP and FAST scores.
• Companies like Madrigal Pharmaceuticals with their drug Resmetirom have shown positive results in NASH, but MetaVia's approach with a GPR119 agonist offers a different mechanism of action.
• The reduction in HbA1c levels is also notable, as it suggests a potential benefit for patients with both MASH and type 2 diabetes, which is a common comorbidity.
• The safety profile of DA-1241 appears to be favorable compared to some other MASH treatments that have shown more significant side effects.

Stakeholder Impact

• Shareholders are likely to react positively to the positive clinical trial results and the company's progress.
• Employees may be motivated by the company's progress and potential for success.
• Patients with MASH may benefit from the development of a new treatment option.
• The company's strategic partner, Dong-A ST, is likely to be pleased with the positive results.

Next Steps

• MetaVia plans to meet with the FDA in the first half of 2025 to discuss the next steps for DA-1241.
• The company expects interim data from the multiple ascending dose (MAD) part of the Phase 1 trial for DA-1726 in Q1 2025.
• The company will release other exploratory endpoints including MRI-PDFF at major future medical conferences.

Key Dates

Keywords

MASH, NASH, DA-1241, GPR119 agonist, ALT, CAP score, FAST score, HbA1c, Clinical Trial, FDA, Obesity, DA-1726, GLP1R/GCGR dual agonist